Latest News On NIH

Latest KFF Health News Stories

How Fauci and the NIH Got Ahead of the FDA and CDC in Backing Boosters

KFF Health News Original

With real-time data streaming in from highly specialized researchers in the U.S. and abroad, NIH scientists became convinced that boosting the covid-19 vaccine was needed to save lives, prompting the president to announce a plan with a Sept. 20 start date. Scientists at the regulatory agencies weren’t yet convinced. A meeting Friday will determine what happens next. Here’s the story from behind the scenes.

Microbiome Startups Promise to Improve Your Gut Health, but Is the Science Solid?

KFF Health News Original

A raft of startups are charging consumers hundreds of dollars to analyze the microbes in their gut and offer dietary advice based on the results. But scientists say scant research has been done, and as customers of one company have learned the hard way, the experience isn’t always smooth.

Paying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead?

KFF Health News Original

Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.

Scientists Seek Covid Treatment Answers in Cheap, Older Drugs

KFF Health News Original

Philanthropies are funding studies of cheap, existing medications like the antidepressant fluvoxamine as covid treatments. But early hype about hydroxychloroquine and other repurposed drugs leaves researchers leery of hasty conclusions.

How Much of Trump’s Health Agenda Has Biden Undone?

KFF Health News Original

In his campaign, President Joe Biden promised to undo policies, particularly health policies, implemented by former President Donald Trump. Yet, despite immense executive power, reversing four years of action takes time and resources.

Take It From an Expert: Fauci’s Hierarchy of Safety During COVID

KFF Health News Original

In a new interview, the nation’s top infectious disease expert tells us how to survive the coming months and describes how hard it is when people still insist the coronavirus outbreak is “fake news.”

KHN’s ‘What the Health?’: What Would Dr. Fauci Do?

KFF Health News Original

Anthony Fauci is one of the nation’s most trusted voices during public health emergencies. As the head of the National Institutes of Health’s National Institute of Allergy and Infectious Diseases since 1984, Fauci has helped guide the nation through the HIV/AIDS epidemic and more recent outbreaks of Ebola and Zika. In this special episode of KHN’s “What the Health?” podcast, Fauci sits down with KHN Editor-in-Chief Elisabeth Rosenthal to talk about how to navigate the next phase of the coronavirus pandemic and what the incoming Biden administration should do first.

These Secret Safety Panels Will Pick the COVID Vaccine Winners

KFF Health News Original

Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.

KHN’s ‘What the Health?’: The Politics of Science

KFF Health News Original

Republicans have all but abandoned the Affordable Care Act as a campaign cudgel, judging from their national convention, at least. Meanwhile, career scientists at the federal government’s preeminent health agencies — the Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institutes of Health — are all coming under increasing political pressure as the pandemic drags on. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss this and more. Plus, Rovner interviews KHN’s Elizabeth Lawrence about the latest KHN-NPR “Bill of the Month” installment.

Dozens of U.S. Hospitals Poised to Defy FDA’s Directive on COVID Plasma

KFF Health News Original

The FDA, under pressure from the Trump administration, has authorized broader use of convalescent plasma for emergency treatment in COVID patients. But several major hospitals are resisting, saying they’ll opt instead to use the scarce resource to complete a clinical trial.